Stomach Cancer Trial, Recruiting NCT06597526 Sponsor: Ruijin Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT06597526
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stomach cancer (gastric adenocarcinoma) confirmed by a tissue sample, and who have not had surgery to remove the primary tumour or any spread of the cancer
  • People whose stomach cancer has spread to the lining of the abdomen (peritoneal metastases), where a keyhole surgical procedure (laparoscopy) is needed to confirm the diagnosis, and who do not have a blockage in the stomach outlet or intestines
  • People who are willing to sign a consent form to take part in the study
  • People aged 18 years or older
  • People with a general health and activity level rated at 2 or below on a standard medical scale (ECOG score), meaning they are able to care for themselves and are up and about for more than half of waking hours (confirm with trial site)
  • People with a life expectancy of at least 3 months
  • People whose liver, kidneys, and bone marrow are functioning well enough to meet the study's requirements (confirm with trial site)
  • People who are willing to follow the study schedule and attend all required follow-up appointments

Who may not be able to join:

  • People who have cancer that has spread to areas other than the abdominal lining at the time of enrolment
  • People who are pregnant or breastfeeding
  • People who have had another type of cancer in the past 5 years, with the exception of certain fully treated skin cancers or early-stage cervical changes (carcinoma in situ)
  • People with a severe mental health condition, uncontrolled epilepsy, or a disease affecting the brain or nervous system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0086-13524945287

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
15 June 2024
Est. completion
31 March 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Target-to-background ratio(TBR); Standardized uptake value(SUV); Evaluation the outcome of conversion therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov